オシメルチニブ医薬品の世界市場レポート 2024

オシメルチニブ医薬品の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には16.1%の年間複合成長率（CAGR）で120億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、患者中心のケアの強化、進行中の臨床試験と調査、精密医療の統合、価格設定とアクセスに関する取り組み、および世界市場の拡大に起因すると考えられます。予測期間中に予想される主な動向には、バイオシミラーの参入と市場競争の激化、リキッドバイオプシーの採用、ゲノムプロファイリングの進歩、耐性管理戦略、免疫療法併用試験の探索などが含まれます。

肺がんの発生率の予想される増加は、オシメルチニブ医薬品市場の成長を促進すると予想されます。肺組織、特に気道の内側を覆う細胞に発生する肺がんは、がん細胞の増殖と転移に関与する特定のタンパク質をブロックする治療薬オシメルチニブの標的となっています。米国がん協会によると、米国では2022年に約23万6,740人の肺がんと診断された症例があり、その数は2023年までに23万8,340人に増加しました。その結果、肺がんの発生率の増加は、オシメルチニブ医薬品市場の成長を推進する重要な要因となっています。

肺がんのケアと治療の改善を目的とした組織による取り組みにより、オシメルチニブ医薬品市場はさらに拡大すると予想されます。これらの組織的な取り組みには、がんと診断された個人のアクセスのしやすさ、手頃な価格、ケアの質の向上を目的とした政策、資金提供、プログラムが含まれます。注目すべきは、Lung Ambition Allianceが2021年 9月に肺がんケアのイニシアチブ（ILC2）を開始したことです。これは、世界中の肺がんケアの改善に特化した世界のプログラムです。このプログラムは、肺がん管理における世界のばらつきを認識し、肺がん治療における目に見える改善を達成することに重点を置いたプロジェクトに資金を提供しています。その結果、肺がんのケアと治療を向上させるための組織による取り組みの増加が、オシメルチニブ医薬品市場の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のオシメルチニブ医薬品市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 40 mg
• 80 mg
• 世界のオシメルチニブ医薬品市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• ドラッグストアと小売薬局
• オンライン薬局
• 世界のオシメルチニブ医薬品市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 局所進行性非小細胞肺がん（NSCLC）
• 転移性非小細胞肺がん（NSCLC）
• その他の用途

第7章 地域および国の分析

• 世界のオシメルチニブ医薬品市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のオシメルチニブ医薬品市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オシメルチニブ医薬品市場の競合情勢
• オシメルチニブ医薬品市場の企業プロファイル
  • Syndax Pharmaceuticals Ltd.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • AstraZeneca plc
  • Amgen Inc.

第31章 その他の大手および革新的な企業

• Sandoz International GmbH
• Incyte Corporation
• Dr. Reddys Laboratories Ltd.
• Cipla Limited
• Seagen Inc.
• Zydus Lifesciences Limited
• Sun Pharmaceutical Industries Ltd.
• Alembic Pharmaceuticals Limited
• Aristo Pharmaceuticals Private Limited
• Incepta Pharmaceuticals Ltd.
• Accord Healthcare Limited
• Asmo Corporation
• Beacon Pharmaceutical Limited
• Clearsynth Labs Limited
• Apino Pharma Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Osimertinib is a medication prescribed for the treatment of non-small cell lung cancer (NSCLC) in patients with specific abnormal epidermal growth factor (EGFR) genes. As a kinase inhibitor, it functions by blocking the action of the abnormal protein that signals cancer cells to multiply.

The main types of osimertinib drugs are available in 40mg and 80mg dosages. The 40mg designation represents the strength of the Osimertinib tablet. These medications are distributed through various channels, including hospital pharmacies, drugstores, retail pharmacies, and online pharmacies, catering to conditions such as locally advanced non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer (NSCLC), and others.

The osimertinib drugs market research report is one of a series of new reports from The Business Research Company that provides osimertinib drugs market statistics, including osimertinib drugs industry global market size, regional shares, competitors with an osimertinib drugs market share, detailed osimertinib drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osimertinib drugs industry. This osimertinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osimertinib drugs market size has grown rapidly in recent years. It will grow from $5.66 billion in 2023 to $6.66 billion in 2024 at a compound annual growth rate (CAGR) of 17.8%. The growth observed during the historical period can be attributed to research and development (R&D) investment and innovation, the introduction of targeted therapy, the success of clinical trials, resistance to previous treatments, and improvements in safety profiles.

The osimertinib drugs market size is expected to see rapid growth in the next few years. It will grow to $12.09 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The anticipated growth in the forecast period can be attributed to enhancements in patient-centric care, ongoing clinical trials and research, the integration of precision medicine, initiatives related to pricing and access, and the expansion of the global market. Major trends expected during the forecast period include the entry of biosimilars and increased market competition, the adoption of liquid biopsy, advancements in genomic profiling, strategies for managing resistance, and the exploration of immunotherapy combination trials.

The anticipated rise in the incidence of lung cancer is set to drive the growth of the osimertinib drug market. Lung cancer, originating in the lung tissues, particularly in cells lining the airways, is a target for osimertinib, a therapeutic drug that blocks specific proteins involved in the growth and spread of cancer cells. According to the American Cancer Society, the United States witnessed around 236,740 diagnosed lung cancer cases in 2022, a number that has increased to 238,340 by 2023. Consequently, the escalating incidence of lung cancer stands as a significant factor propelling the osimertinib drug market's growth.

Initiatives from organizations aimed at improving lung cancer care and treatment are expected to further boost the osimertinib drug market. These organizational initiatives involve policies, funding, and programs geared towards enhancing the accessibility, affordability, and quality of care for individuals diagnosed with cancer. Notably, the Lung Ambition Alliance launched Initiatives in Lung Cancer Care (ILC2) in September 2021, a global program dedicated to improving lung cancer care worldwide. The program, recognizing variations in lung cancer management globally, provides funding for projects focused on achieving measurable enhancements in lung cancer care. Consequently, the increasing initiatives from organizations to elevate lung cancer care and treatment act as a driving force for the osimertinib drug market.

The high costs associated with osimertinib are expected to impede market growth. Factors contributing to the high cost include research and development expenses, the complexity of the manufacturing process, and the limited patient population. According to the National Institutes of Health (NIH), the average monthly cost of osimertinib in the United States ranges from $9,117.36 to $17,028.90. Additionally, its initial commercialization cost in China was $251.78 per day, significantly higher than other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as gefitinib at $34.92 per day. Consequently, the substantial costs associated with osimertinib pose a constraint on the drug market's growth.

Major companies operating in the osimertinib market are strategically focusing on developing innovative drugs to secure their position in the market. The increasing need for more effective and safer treatments has led to drug approvals such as Tagrisso. Tagrisso (osimertinib), a targeted therapy medication for non-small-cell lung cancer, received approval from AstraZeneca in May 2021. The drug inhibits the activation of the EGFR protein, slowing the growth and spread of cancer cells.

In October 2022, Ikena Oncology collaborated with AstraZeneca to explore the potential combination of IK-930 and osimertinib for enhanced efficacy and safety in treating EGFR-mutated non-small-cell lung cancer (NSCLC). This collaboration is a strategic move to leverage the expertise of both companies in advancing treatment options.

Major companies operating in the osimertinib drugs market report are Syndax Pharmaceuticals Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, AstraZeneca plc, Amgen Inc., Sandoz International GmbH, Incyte Corporation, Dr. Reddys Laboratories Ltd., Cipla Limited, Seagen Inc., Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Accord Healthcare Limited, Asmo Corporation, Beacon Pharmaceutical Limited, Clearsynth Labs Limited, Apino Pharma Co. Ltd., Kay Biotech Private Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Array BioPharma Inc., Dolphin Pharmaceutical Limited, Hetero Drugs Ltd., Serum Biotech Limited, Zenix Remedies, Accure Labs Pvt. Ltd.

North America was the largest region in the osimertinib drugs market in 2023. The regions covered in the osimertinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the osimertinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The osimertinib drugs market consists of sales of tagrisso, osi-TKI, and osimertinib mesylate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osimertinib Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osimertinib drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osimertinib drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osimertinib drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: 40 mg; 80 mg
• 2) By Distribution Channel: Hospital Pharmacy; Drug Store And Retail Pharmacy; Online Pharmacy
• 3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC); Other Applications
• Companies Mentioned: Syndax Pharmaceuticals Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; AstraZeneca plc; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osimertinib Drugs Market Characteristics

3. Osimertinib Drugs Market Trends And Strategies

4. Osimertinib Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Osimertinib Drugs Market Size and Growth

• 5.1. Global Osimertinib Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Osimertinib Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Osimertinib Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Osimertinib Drugs Market Segmentation

• 6.1. Global Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

40 mg

80 mg

• 6.2. Global Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Drug Store And Retail Pharmacy
• Online Pharmacy
• 6.3. Global Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
• Metastatic Non-Small Cell Lung Cancer (NSCLC)
• Other Applications

7. Osimertinib Drugs Market Regional And Country Analysis

• 7.1. Global Osimertinib Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Osimertinib Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Osimertinib Drugs Market

• 8.1. Asia-Pacific Osimertinib Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Osimertinib Drugs Market

• 9.1. China Osimertinib Drugs Market Overview
• 9.2. China Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Osimertinib Drugs Market

• 10.1. India Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Osimertinib Drugs Market

• 11.1. Japan Osimertinib Drugs Market Overview
• 11.2. Japan Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Osimertinib Drugs Market

• 12.1. Australia Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Osimertinib Drugs Market

• 13.1. Indonesia Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Osimertinib Drugs Market

• 14.1. South Korea Osimertinib Drugs Market Overview
• 14.2. South Korea Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Osimertinib Drugs Market

• 15.1. Western Europe Osimertinib Drugs Market Overview
• 15.2. Western Europe Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Osimertinib Drugs Market

• 16.1. UK Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Osimertinib Drugs Market

• 17.1. Germany Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Osimertinib Drugs Market

• 18.5. France Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Osimertinib Drugs Market

• 19.9. Italy Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Osimertinib Drugs Market

• 20.13. Spain Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Osimertinib Drugs Market

• 21.1. Eastern Europe Osimertinib Drugs Market Overview
• 21.2. Eastern Europe Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Osimertinib Drugs Market

• 22.1. Russia Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Osimertinib Drugs Market

• 23.1. North America Osimertinib Drugs Market Overview
• 23.2. North America Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Osimertinib Drugs Market

• 24.1. USA Osimertinib Drugs Market Overview
• 24.2. USA Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Osimertinib Drugs Market

• 25.1. Canada Osimertinib Drugs Market Overview
• 25.2. Canada Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Osimertinib Drugs Market

• 26.1. South America Osimertinib Drugs Market Overview
• 26.2. South America Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Osimertinib Drugs Market

• 27.1. Brazil Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Osimertinib Drugs Market

• 28.1. Middle East Osimertinib Drugs Market Overview
• 28.2. Middle East Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Osimertinib Drugs Market

• 29.1. Africa Osimertinib Drugs Market Overview
• 29.2. Africa Osimertinib Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Osimertinib Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Osimertinib Drugs Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Osimertinib Drugs Market Competitive Landscape And Company Profiles

• 30.1. Osimertinib Drugs Market Competitive Landscape
• 30.2. Osimertinib Drugs Market Company Profiles
  • 30.2.1. Syndax Pharmaceuticals Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AstraZeneca plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Amgen Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Osimertinib Drugs Market Other Major And Innovative Companies

• 31.1. Sandoz International GmbH
• 31.2. Incyte Corporation
• 31.3. Dr. Reddys Laboratories Ltd.
• 31.4. Cipla Limited
• 31.5. Seagen Inc.
• 31.6. Zydus Lifesciences Limited
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Alembic Pharmaceuticals Limited
• 31.9. Aristo Pharmaceuticals Private Limited
• 31.10. Incepta Pharmaceuticals Ltd.
• 31.11. Accord Healthcare Limited
• 31.12. Asmo Corporation
• 31.13. Beacon Pharmaceutical Limited
• 31.14. Clearsynth Labs Limited
• 31.15. Apino Pharma Co. Ltd.

32. Global Osimertinib Drugs Market Competitive Benchmarking

33. Global Osimertinib Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Osimertinib Drugs Market

35. Osimertinib Drugs Market Future Outlook and Potential Analysis

• 35.1 Osimertinib Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Osimertinib Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Osimertinib Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer